par Mauriac, Louis;Keshaviah, A;Debled, M;Mouridsen, Henning;Forbes, John F;Thürlimann, Beat;Paridaens, R. 
;Monnier, A;Láng, I;Wardley, Andrew;Nogaret, Jean-Marie ;Gelber, R D;Castiglione-Gertsch, Monica;Price, K;Coates, Alan;Smith, Ian;Viale, Giuseppe;Rabaglio, M;Zabaznyi, N;Goldhirsch, Aron;BIG 1-98 Collaborative Group, ;International Breast Cancer Study Group,
Référence Annals of oncology, 18, 5, page (859-867)
Publication Publié, 2007-05
;Monnier, A;Láng, I;Wardley, Andrew;Nogaret, Jean-Marie ;Gelber, R D;Castiglione-Gertsch, Monica;Price, K;Coates, Alan;Smith, Ian;Viale, Giuseppe;Rabaglio, M;Zabaznyi, N;Goldhirsch, Aron;BIG 1-98 Collaborative Group, ;International Breast Cancer Study Group, Référence Annals of oncology, 18, 5, page (859-867)
Publication Publié, 2007-05
Article révisé par les pairs
| Résumé : | Aromatase inhibitors are considered standard adjuvant endocrine treatment of postmenopausal women with hormone receptor-positive breast cancer, but it remains uncertain whether aromatase inhibitors should be given upfront or sequentially with tamoxifen. Awaiting results from ongoing randomized trials, we examined prognostic factors of an early relapse among patients in the BIG 1-98 trial to aid in treatment choices. |
